Biomarkers for determination of temporal phase of acute kidney injury

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9238837
APP PUB NO 20130165338A1
SERIAL NO

13704652

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to a method for determining the temporal phase of acute kidney injury, comprising obtaining a test sample from a subject and measuring the expression level of at least one biomarker selected from the group comprising Chac1, Birc5 and Angptl7. The invention also relates to a method for determining the early early phase, the late early phase, the severity and/or timing of acute kidney injury via analysis of the biomarkers Chac1, Birc5 and/or Angptl7, in addition to a test kit for carrying out said methods and antibodies directed against Chac1, Birc5 or Angptl7.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZINROBERT-ROESSLE-STRASSE 10 BERLIN 13125

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Schmidt-Ott, Kai Berlin, DE 2 13
Wuebken, Anne Berlin, DE 1 7

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 19, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00